Prevalence of elevated blood lead levels and evaluation of a lead-risk-screening questionnaire in rural Minnesota.

The objectives of the study reported here were to determine the prevalence of elevated blood lead levels in rural Minnesota and to evaluate a lead-risk-screening questionnaire. Blood lead tests and lead risk questionnaires were obtained for a sample of 1,090 children younger than 48 months of age (72 percent of the eligible population) from three rural counties of west-central Minnesota between September 1, 2001, and August 31, 2002. It was found that overall, 2.4 percent of children in the study had blood lead levels of > or = 10 microg/dL (0.48 micromol/L) (results for capillary and venous tests combined), 0.9 percent had venous blood lead levels of > or = 10 microg/dL, and 0.5 percent of study participants had blood lead levels of > or = 20 microg/dL (0.96 micromol/L). Three risk factor questions, when taken together, predicted 90 percent of blood lead levels of > or = 10 microg/dL and all blood lead levels of > or = 20 microg/dL. The study estimated the prevalence of lead poisoning using a sample of the entire population rather than a clinic-based convenience sample. The authors conclude that targeted screening is an effective way to identify lead-poisoned children in rural areas of Minnesota.

Adult blood lead epidemiology and surveillance--United States, 1998-2001.

PROBLEM/CONDITION: Elevated blood lead levels (BLLs) in adults can damage the cardiovascular, central nervous, reproductive, hematologic, and renal systems. The majority of cases are workplace-related. U.S. Department of Health and Human Services recommends that BLLs among all adults be reduced to < 25 microg/dL. The highest BLL acceptable by standards of the U.S. Occupational Safety and Health Administration is 40 microg/dL. The mean BLL of adults in the United States is < 3 microg/dL. REPORTING PERIOD: This report covers cases of adults (aged > or = 16 years) with BLLs > or = 25 microg/dL, as reported by 25 states during 1998-2001. DESCRIPTION OF SYSTEM: Since 1987, CDC has sponsored the state-based Adult Blood Lead Epidemiology and Surveillance (ABLES) program to track cases of elevated BLLs and provide intervention consultation and other assistance. Overall ABLES program data were last published in 1999 for the years 1994-1997. This report provides an update with data from 25 states reporting for > or = 2 years during 1998-2001. During that period, the ABLES program funded surveillance in 21 states - Alabama, Arizona, Connecticut, Iowa, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Washington, Wisconsin, and Wyoming. Four additional states - California, Nebraska, New Hampshire, and Utah contributed data without CDC funding. RESULTS: During 1998-2001, the overall program's annual mean state prevalence rate for adults with BLLs > or = 25 microg/dL was 13.4/100,000 employed adults. This compares with 15.2/100,000 for 1994-1997. Yearly rates were 13.8 (1998), 12.9 (1999), 14.3 (2000), and 12.5 (2001). For adults with BLLs > or = 40 microg/dL, the overall program's annual mean state prevalence rare during 1998-2001 was 2.9/ 100,000 employed adults. This compares with 3.9/100,000 for 1994-1997. Yearly rates were 3.3 (1998), 2.5 (1999), 2.9 (2000), and 2.8 (2001). INTERPRETATION: Although certain limitations exist, the overall ABLES data indicate a declining trend in elevated BLLs among employed adults. PUBLIC HEALTH ACTIONS: ABLES-funded states increased from 21 to 35 in 2002, and more detailed reporting requirements were put into effect. These, and other improvements, will enable the ABLES program to work more effectively toward its 2010 target of eliminating all cases of BLLs > or = 25 microg/dL in adults caused by workplace exposures.